TRAIL R2 Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2024

TRAIL R2 agonist is a pharmaceutical agent that targets the TRAIL receptor 2 (TNF-related apoptosis-inducing ligand receptor 2) to induce apoptosis (programmed cell death) in cancer cells. By binding to TRAIL R2 on the surface of cancer cells, this agonist triggers a signalling cascade that leads to cell death, inhibiting tumor growth. TRAIL R2 agonists are primarily used in the treatment of various cancer types, including lung cancer, breast cancer, and colorectal cancer. TRAIL R2 agonist is a pharmaceutical agent that targets the TRAIL receptor 2 (TNF-related apoptosis-inducing ligand receptor 2) to induce apoptosis (programmed cell death) in cancer cells. By binding to TRAIL R2 on the surface of cancer cells, this agonist triggers a signaling cascade that leads to cell death, inhibiting tumor growth.

TRAIL R2 agonists are primarily used in the treatment of various lymphoma, carcinoma, bronchial neoplasms, colonic diseases, digestive system diseases, immunoproliferative disorders, endocrine gland disorders, lung diseases, ovarian cancers, and breast cancers to name a few. According to WHO, cancer is a leading cause of death in both Europe and the USA. In Europe, it accounts for nearly 1.9 million deaths annually, with lung cancer being the most common cause, followed by breast and colorectal cancers. In the USA, cancer-related deaths reach around 600,000 each year, with lung, breast, and colorectal cancers as the top contributors. The prevalence of these indications necessitates effective treatments like TRAIL R2 agonists to combat the disease burden. Growth drivers of the TRAIL R2 agonist market include increasing research and development in oncology, rising cancer incidence, and the demand for targeted therapies. Moreover, to address the difficulties in therapy, numerous industry players are developing innovative compounds. For instance, Amgen’s Conatumumab (AMG 655) for the treatment of colorectal cancer is in the various stages of clinical studies.

Key Market Developments:

• In October 2021, Clover Biopharmaceuticals completed phase 1, a study evaluating the safety, tolerability, and pharmacokinetics of SCB-313, a fully human TRAIL-Trimer fusion protein, for the treatment of peritoneal malignancies.

Drugs under the Pipeline for TRAIL R2 Agonists:

• Conatumumab (AMG 655)
• Tigatuzumab (CS-1008)
• Dulanermin (AMG 951)
• SCB-313
• DS-8273
• BI 905711
• INBRX-109
• Eftozanermin Alfa (ABBV-621)
• IGM-8444
• Benufutamab (GEN1029)

Clinical Activity and Developments of TRAIL R2 Agonists:

Till July 2023, more than 10 companies have approximately 10 molecules targetting many cancers. For these molecules, more than 5 clinical trials are being conducted and the majority are in phase-1, and phase-2 clinical trials by players across the globe. For instance,

• In December 2019, Amgen completed phase 2, an open-label extension study of Conatumumab and AMG 479 to evaluate the safety.